Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Interim 24-week results from a Phase III study
comparing the investigatory dolutegravir to raltegravir among
HIV-positive individuals who...
Gilead Sciences has begun two Phase III clinical trials of a single-tablet, once-a-day antiretroviral regimen containing TAF.
Stribild—the new quad combo pills—is non-inferior to both Atripla and to ritonavir-boosted atazanavir plus Truvada in first-time...
Dolutegravir, an experimental once-daily integrase inhibitor being developed by ViiV Healthcare and Shionogi, combined with Epzicom, appears t...
A study of Gilead Sciences’ “Quad” fixed-dose combination tablet containing the experimental integrase inhibitor elvitegravir and...
ViiV Healthcare and Shionogi have launched an expanded access program (EAP) for its integrase inhibitor dolutegravir (S/GSK134957), according...
Merck will delay its request for U.S. Food and Drug Administration (FDA) approval for vicriviroc, an experimental CCR5 antagonist, after...
Avexa announced it is closing a planned 48-week Phase III study early in order to analyze the data and make decisions about the drug’s fate
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.